Abemaciclib is an orally administered selective CDK4/6 inhibitor that arrests the cell cycle at the G1-to-S transition in hormone receptor-positive breast cancer cells, typically used in combination with endocrine therapy. As a targeted oncology agent, precise impurity and degradation profiling is essential for both originator and generic manufacturers. Simson Pharma offers an Abemaciclib reference standard and related impurities to support this analytical demand.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Abemaciclib Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.